Background: Early identification of the risk of early cancer-related death (within one year, ECRD) due to recurrence after liver resection for hepatocellular carcinoma (HCC) patients with Barcelona Clinic Liver Cancer (BCLC) stage B/C is important for surgeons to make clinical decisions. Our study aimed to establish a nomogram to predict the ECRD due to recurrence for HCC patients with BCLC stage B/C.
Methods: A total of 672 HCC patients with BCLC stages B/C from four medical centers between January 2012 and December 2018 were included in our study. The patients were randomly divided into a training cohort (n = 404) and a validation cohort (n = 268) at a ratio of 6:4. The least absolute shrinkage and selection operator (LASSO) logistic regression model was used to establish a nomogram model.
Results: In our LASSO-logistic regression model, three variables were independently associated with the ECRD due to recurrence: the alpha-fetoprotein-tumor burden score (ATS score, Odd Ratio [OR]: 1.12, p = 0.001), BCLC stage (OR: 4.39, p < 0.001) and the aspartate transaminase (AST) to alanine transaminase (ALT) ratio (AAR, OR: 1.49, p = 0.027) and we established the nomogram model based on these three variables. The nomogram model showed superior predictive ability in the training cohort (Area under the curve [AUC]: 0.754, 95%CI: 0.703-0.804) and the validation cohort (AUC: 0.741, 95%CI: 0.660-0.823). Compared with the ATS score, BCLC stage and AAR, the nomogram both had better predictive ability in both the training cohort (ATS score, AUC: 0.699, 95%CI: 0.646-0.752, p = 0.010; BCLC stage, AUC: AUC: 0.684, 95%CI: 0.637-0.732, p < 0.001; AAR, AUC: 0.593, 95%CI: 0.522-0.663, p < 0.001) and the validation cohort (ATS score, AUC: 0.659, 95%CI: 0.577-0.740, p = 0.002; BCLC stage, AUC: 0.688, 95%CI: 0.622-0.753, p = 0.009; AAR, AUC: 0.540, 95%CI: 0.436-0.645, p < 0.001).
Conclusions: We established a nomogram that had excellent predictive power for predicting the ECRD due to recurrence in HCC patients with BCLC stage B/C, which might help surgeons to avoid futile liver resection.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11727159 | PMC |
http://dx.doi.org/10.1186/s12876-025-03588-6 | DOI Listing |
J Hepatocell Carcinoma
January 2025
Department of Medical Oncology, Peking University International Hospital, Beijing, People's Republic of China.
Background: The prognosis is extremely troubling in advanced hepatocellular carcinoma (HCC). Prognostic scores have been developed. Yet, the positive predictive values might appear inadequate.
View Article and Find Full Text PDFAnal Cell Pathol (Amst)
January 2025
School of Public Health, Chengdu Medical College, Chengdu, Sichuan, China.
DEAD-box helicase 21 (DDX21) is a conserved Asp-Glu-Ala-Asp (DEAD) box RNA helicase with multiple functions that is involved in various cellular processes and diseases. However, the role of DDX21 in the recurrence and prognosis of hepatocellular carcinoma (HCC) patients remains unknown. In the current study, we examined the protein expression of DDX21 in HCC tissues through immunohistochemical staining and analyzed the correlation between DDX21 protein expression and clinical outcome via Kaplan-Meier survival analysis.
View Article and Find Full Text PDFCancers (Basel)
January 2025
Department of Medical and Surgical, Maternal-Infantile and Adult Sciences, University of Modena and Reggio Emilia, 41126 Modena, Italy.
Background And Aims: Hepatocellular carcinoma (HCC) represents the second leading cause of cancer deaths worldwide. Six-month imaging along with alpha-fetoprotein (AFP) serum levels detection are the current gold standard to exclude HCC. Protein induced by vitamin K absence (PIVKA-II) has been proposed as a potential screening biomarker for HCC.
View Article and Find Full Text PDFGastroenterology
January 2025
Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Background & Aims: This study aimed to compare ultrasonography (US) and non-contrast magnetic resonance imaging (MRI) in the surveillance of hepatic malignancy.
Methods: We conducted a randomized, non-blinded, single-center trial at a single center in South Korea. Eligible individuals were aged 20-70 years with liver cirrhosis, Child-Pugh class A, and no history of liver cancer or other recent malignancy.
Surg Endosc
January 2025
Division of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Guangxi, China.
Background: Both laparoscopic hepatectomy (LH) and robotic hepatectomy (RH) have been performed for tumors in nearly all liver segments. However, few studies have compared the outcomes of patients who underwent open hepatectomy (OH), LH and RH for the treatment of Barcelona Clinic Liver Cancer (BCLC) stage 0-A HCC in S7/8.
Methods: The clinical data of patients who underwent S7/8 resection for the treatment of BCLC stage 0-A HCC in the First Affiliated Hospital of Guangxi Medical University from July 2017 to July 2023 were retrospectively collected.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!